MAF (gene)

Genprex Provides Business Update and Outlook for 2024

Retrieved on: 
Friday, January 5, 2024
NPRL2, Atezolizumab, FDA, Lung cancer, Cancer, MAF (gene), University of Pittsburgh, Treatment, SCLC, Autoimmunity, Pembrolizumab, Conference, Type 1, IND, Pancreas, Disease, Orphan, ATTD, University, Carcinoma, Merck, NSCLC, Patient, AACR, Food, Neoplasm, Immune system, AstraZeneca, Type 2, Apoptosis, Tumor suppressor gene, AAV, Toxicity, MAFB (gene), Genentech, NHP, Research, Insulin, C-peptide, Clinical trial, Investigational New Drug, PDX1, Pharmaceutical industry

AUSTIN, Texas, Jan. 5, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today provides a review of its 2023 achievements and a preview of plans for advancing its diabetes and oncology gene therapy programs in 2024.

Key Points: 
  • Our accomplishments in 2023, which also include process improvements in our manufacturing operations and securing new supplies of REQORSA, sets the foundation for a strong 2024."
  • Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Nanoparticle Delivery System which encapsulates the gene-expressing plasmids using lipid nanoparticles.
  • In May, Genprex completed the Phase 1 portion of the Acclaim-1 clinical trial and reported encouraging results.
  • In October 2023, Genprex entered into a one-year extension to the August 2022 sponsored research agreement with the University of Pittsburgh.

Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh

Retrieved on: 
Tuesday, July 18, 2023
C-peptide, Insulin, Human, MAFB (gene), University, Pediatrics, Diabetes, Pancreas, Cancer, Pitt, University of Pittsburgh School of Medicine, AAV, Patent, MD, Patient, Division, Immune system, Pancreatic duct, MAF (gene), NHP, Wilfrid Sellars, Gene, PDX1, Disease, Pharmaceutical industry

AUSTIN, Texas, July 18, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement with the University of Pittsburgh (Pitt), granting Genprex a worldwide, exclusive license to a patent application and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to a gene therapy for both Type 1 and Type 2 diabetes using the genes of the Pdx1 and MafA transcription factors controlled by a MafB promoter. 

Key Points: 
  • "We are continuing to build a fortress of protection and a powerful intellectual property portfolio for our diabetes gene therapy program.
  • The addition of this license to MafB promoter technology expands and strengthens the potential for this novel, gene therapy to treat Type 1 and Type 2 diabetes," said Rodney Varner, Chairman, President and Chief Executive Officer at Genprex.
  • "In licensing this latest exclusive technology, which joins several others that provide us with multiple diabetes gene therapy combinations, we have valuable rights over what we believe are the most innovative, emerging diabetes gene therapies."
  • Earlier this year, the Company's research collaborators at the University of Pittsburgh presented preclinical data in a Non-Human Primate (NHP) model of Type 1 diabetes highlighting the therapeutic potential of GPX-002.

Genprex Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Gene Therapy to Treat Type 1 Diabetes at 16th Annual International Conference on Advanced Technologies & Treatment for Diabetes 2023

Retrieved on: 
Thursday, February 23, 2023
MAF (gene), Primate, Insulin, Pitt, PDX1, University, Cancer, MD, DO, Defence Institute of Advanced Technology, Treatment, International Conference on Creationism, Patient, Pancreas, Pediatric surgery, AAV, Type 1, Conference, Streptozotocin, C-peptide, ATTD, Pharmaceutical industry, Medical device, Diabetes

AUSTIN, Texas, Feb. 23, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that data highlighting the potential of Genprex's gene therapy for Type 1 diabetes is being presented by its research collaborators at the University of Pittsburgh (Pitt) at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) taking place February 22-25, 2023 in Berlin, Germany. 

Key Points: 
  • The complete presentation will be available on the Company's website here following the close of Dr. Kalsi's presentation.
  • They received a novel infusion process that used an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas.
  • "These results are compelling as they demonstrate the potential for this gene therapy to create newly formed beta-like cells that can produce insulin.
  • Importantly, it shows a positive data progression from our earlier mouse model data to these NHP data," noted Dr. Gittes.

Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh

Retrieved on: 
Thursday, January 5, 2023
Cancer, Pancreas, University, Mouse, Insulin, Glucagon, MD, Type 1, AAV, Diabetes, Factor X, PDX1, Autoimmunity, Division, Wilfrid Sellars, Disease, Patient, Pediatrics, Type 2, Macrophage, Type 2 diabetes, Pitt, University of Pittsburgh School of Medicine, MAF (gene), Patent, Immune system, Human, Gene, Pharmaceutical industry

AUSTIN, Texas, Jan. 5, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement (the Agreement) with the University of Pittsburgh (Pitt), granting Genprex a worldwide, exclusive license to a patent application and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to gene therapy for Type 2 diabetes using the genes of the Pdx1 and MafA transcription factors. The preclinical technology, GPX-003, is believed to work by rejuvenating diminished beta cells to increase insulin expression by introducing transcription factors controlled by an insulin promoter.

Key Points: 
  • "This marks the Company's third technology license this year supporting our diabetes program, demonstrating the continued strengthening of our intellectual property portfolio, our diabetes program, and our position as a lead innovator in emerging diabetes gene therapies," said Rodney Varner, President and Chief Executive Officer of Genprex.
  • "We are thrilled to have secured multiple cutting edge technologies from Pitt that expand our diabetes gene therapy program and specifically target Type 1 and Type 2 diabetes."
  • Genprex recently announced a license agreement with the University of Pittsburgh for a preclinical technology that transforms macrophages enabling them to reduce autoimmune activity in Type 1 diabetes, a technology that could be complementary to the Company's GPX-002 diabetes technology.
  • More than 537 million people around the world have diabetes, and in the U.S. alone, there are 37.3 million people with diabetes.

Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabetes

Retrieved on: 
Wednesday, January 4, 2023
Human, University, Protein, Autoimmunity, Wilfrid Sellars, Security (finance), Central European, Type 1, Annual report, Patient, Type 2, Food, Squamous cell carcinoma, Medicine, Immune system, Intellectual property, Large-cell lung carcinoma, Honda advanced technology, ATTD, Tumor suppressor gene, Growth, COVID-19, Food and Drug Administration Amendments Act of 2007, Division, Pediatric surgery, Conference, MAF (gene), AAV, MD, Gene, Mouse, Treatment, Pittsburgh, Uncertainty, Pancreas, Pediatrics, Risk, NSCLC, DO, International Conference on Emerging Infectious Diseases, Insulin, Research, Cancer, Pharmaceutical industry, Vaccine, Audit, Diabetes, PDX1

AUSTIN, Texas, Jan. 4, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators at the University of Pittsburgh will present preclinical data highlighting the therapeutic potential of Genprex's gene therapy for Type 1 diabetes at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) being held February 22-25 in Berlin, Germany and online.

Key Points: 
  • "ATTD 2023 presents an ideal opportunity for the results of this important study to be presented to the diabetes community.
  • The diabetes gene therapy approach is comprised of a novel infusion process that uses endoscopic delivery of an adeno-associated virus (AAV) vector to bring therapeutic genes directly to the pancreas.
  • Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options.
  • You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

Genprex to Present at Upcoming December Investor Conference

Retrieved on: 
Friday, December 2, 2022
NSCLC, PDX1, Type 2, COVID-19, Insulin, MAF (gene), Human, Intellectual property, Pancreas, Tumor suppressor gene, Type 1, Diabetes, Large-cell lung carcinoma, Immune system, Cancer, Conference, Squamous cell carcinoma, Annual report, Risk, Growth, Q&A, Food, Food and Drug Administration Amendments Act of 2007, AAV, Protein, Autoimmunity, Patient, Security (finance), Gene, General counsel, Uncertainty, Pharmaceutical industry, Audit

AUSTIN, Texas , Dec. 2, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its Executive Vice President, General Counsel and Chief Strategy Officer, Catherine Vaczy, will be providing an overview of the Company's gene therapies for cancer and diabetes at the following investor conference in December 2022.

Key Points: 
  • Ms. Vaczy will be available for Q&A following the presentation and for in-person one-on-one meetings with investors at the RHK Disruptive Growth Conference.
  • Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.
  • Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches.
  • You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all.

Genprex to Present at Upcoming October Investor and Industry Conferences

Retrieved on: 
Friday, October 7, 2022
U.S. Securities and Exchange Commission, Time, Uncertainty, Tumor suppressor gene, Growth, Review, Food and Drug Administration Amendments Act of 2007, Annual report, NASDAQ, Patient, Security (finance), MAF (gene), Cancer, Private Securities Litigation Reform Act, Food, Immune system, Company, NSCLC, PDX1, AAV, Industry, Squamous cell carcinoma, Diabetes, Autoimmunity, Protein, Intellectual property, Insulin, COVID-19, Gene, Pancreas, Human, Large-cell lung carcinoma, Risk, Pharmaceutical industry, Audit, T2D, T1D

AUSTIN, Texas, Oct. 7, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming investor and industry conferences to be held in October 2022.

Key Points: 
  • AUSTIN, Texas, Oct. 7, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming investor and industry conferences to be held in October 2022.
  • For those interested in meeting Genprex management during BIO Europe, please request a meeting through the conference portal or reach out to Kalyn Dabbs at [email protected] .
  • For those interested in meeting Genprex management at LD Micro's Main event, please request a meeting through LD Micro or reach out to Kalyn Dabbs at [email protected] .
  • Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.

Genprex to Present at Upcoming September Investor Conference

Retrieved on: 
Thursday, September 8, 2022
Security (finance), COVID-19, Human, Cancer, MAF (gene), Gene, Large-cell lung carcinoma, NASDAQ, Time, Protein, PDX1, Risk, Food, AAV, U.S. Securities and Exchange Commission, Squamous cell carcinoma, Food and Drug Administration Amendments Act of 2007, Tumor suppressor gene, Insulin, Pancreas, Company, Immune system, NSCLC, Uncertainty, Diabetes, Annual report, Intellectual property, Private Securities Litigation Reform Act, Growth, Review, Patient, Pharmaceutical industry, Audit, T1D

AUSTIN, Texas, Sept. 8, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its Chief Financial Officer, Ryan Confer, will be providing a virtual overview of the Company's gene therapies for cancer and diabetes at the following investor conference in September 2022.

Key Points: 
  • A recording of this presentation will be available for replay on Genprex's website for a period of time.
  • Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.
  • Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches.
  • You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all.